Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
A phase 1/2 trial of Ponatinib in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Incyte Biosciences International Sàrl, now recruiting.
Overview
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors is a phase 1/2 interventional study registered as NCT03934372 by Incyte Biosciences International Sàrl, with 70 participants planned, started 2020-01-29 and due to reach its primary completion in 2028-02-01. Interventions recorded: Ponatinib.
Similar pages
not linked directly; found by shared links- TrialThe Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Shares Ponatinib, Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
- TrialTGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
- TrialStudy of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
- TrialA Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Shares Non-Hodgkin lymphoma (all types), Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.